These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38116167)

  • 1. Histopathology of telomerase reverse transcriptase promoter (
    Pinto JO; Livhits MJ; Yeh MW; Kaykov A; Klopper JP; Kloos RT; Alshalalfa M; Hao Y; Huang J; Endo M
    J Clin Transl Endocrinol; 2024 Mar; 35():100329. PubMed ID: 38116167
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Sfreddo HJ; Koh ES; Zhao K; Swartzwelder CE; Untch BR; Marti JL; Roman BR; Dublin J; Wang RS; Xia R; Cohen JM; Xu B; Ghossein R; Givi B; Boyle JO; Tuttle RM; Fagin JA; Wong RJ; Morris LGT
    Thyroid; 2024 Apr; 34(4):450-459. PubMed ID: 38407967
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictive Value of a Genomic Classifier in Indeterminate Thyroid Nodules Based on Nodule Size.
    Dublin JC; Papazian M; Zan E; Oweity T; Sun W; Jacobson A; Patel K; Brandler TC; Givi B
    JAMA Otolaryngol Head Neck Surg; 2022 Jan; 148(1):53-60. PubMed ID: 34734965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.
    Chin PD; Zhu CY; Sajed DP; Fishbein GA; Yeh MW; Leung AM; Livhits MJ
    Endocr Pathol; 2020 Dec; 31(4):377-384. PubMed ID: 32671653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid Nodules with Indeterminate FNAC According to the Italian Classification System: Prevalence, Rate of Operation, and Impact on Risk of Malignancy. An Updated Systematic Review and Meta-analysis.
    Trimboli P; Ferrarazzo G; Cappelli C; Piccardo A; Castellana M; Barizzi J
    Endocr Pathol; 2022 Dec; 33(4):457-471. PubMed ID: 36044162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.
    Liu R; Xing M
    Endocr Relat Cancer; 2014 Oct; 21(5):825-30. PubMed ID: 25121551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and Significance of
    Censi S; Cavedon E; Bertazza L; Galuppini F; Watutantrige-Fernando S; De Lazzari P; Nacamulli D; Pennelli G; Fassina A; Iacobone M; Casal Ide E; Vianello F; Barollo S; Mian C
    Front Endocrinol (Lausanne); 2017; 8():273. PubMed ID: 29085338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles.
    Elsherbini N; Kim DH; Payne RJ; Hudson T; Forest VI; Hier MP; Payne AE; Pusztaszeri MP
    J Otolaryngol Head Neck Surg; 2022 Nov; 51(1):43. PubMed ID: 36371345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
    Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
    Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of malignancy in cytologically indeterminate thyroid nodules harboring thyroid stimulating hormone receptor mutations.
    Whitmer D; Phay JE; Holt S; O'Donnell B; Nguyen J; Joseph D; Chi A; Wu S; Hao Y; Huang J; Klopper JP; Kloos RT; Kennedy GC; Shin J
    Front Endocrinol (Lausanne); 2022; 13():1073592. PubMed ID: 36619548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
    Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.
    Chen T; Gilfix BM; Rivera J; Sadeghi N; Richardson K; Hier MP; Forest VI; Fishman D; Caglar D; Pusztaszeri M; Mitmaker EJ; Payne RJ
    Thyroid; 2020 Sep; 30(9):1280-1287. PubMed ID: 32242511
    [No Abstract]   [Full Text] [Related]  

  • 13. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
    Macerola E; Rago T; Proietti A; Basolo F; Vitti P
    J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
    Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
    [No Abstract]   [Full Text] [Related]  

  • 15. The utility of ThyroSeq
    Li W; Justice-Clark T; Cohen MB
    Cytopathology; 2021 Jul; 32(4):505-512. PubMed ID: 33914382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital droplet PCR TERT promoter mutational screening in fine needle aspiration cytology of thyroid lesions: A highly specific technique for pre-operative identification of high-risk cases.
    Hysek M; Hellgren LS; Stenman A; Darai-Ramqvist E; Ljung E; Schliemann I; Condello V; Larsson C; Zedenius J; Jatta K; Juhlin CC
    Diagn Cytopathol; 2023 Jun; 51(6):331-340. PubMed ID: 36870048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy.
    Decaussin-Petrucci M; Descotes F; Depaepe L; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Lopez J
    Cytopathology; 2017 Dec; 28(6):482-487. PubMed ID: 29094776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.
    Kim TH; Ki CS; Hahn SY; Oh YL; Jang HW; Kim SW; Chung JH; Shin JH
    Endocrine; 2017 Aug; 57(2):234-240. PubMed ID: 28616852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Indicators of
    Bandargal S; Chen T; Pusztaszeri MP; Forest VI; da Silva SD; Payne RJ
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT Promoter Mutations in Thyroid Cancer.
    Alzahrani AS; Alsaadi R; Murugan AK; Sadiq BB
    Horm Cancer; 2016 Jun; 7(3):165-77. PubMed ID: 26902827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.